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Introduction. Hematological alterations are frequent in malaria patients; the relationship between alterations in white blood cell
counts and clinical status in malaria is not well understood. In Colombia, with low endemicity and unstable transmission for
malaria, with malaria vivax predominance, the hematologic profile in malaria patients is not well characterized. The aim of this
study was to characterize the leukogram in malaria patients and to analyze its alterations in relation to the clinical status.Methods.
888 leukogram profiles ofmalaria patients from different Colombian regions were studied: 556 with P. falciparum infection (62.6%),
313 with P. vivax infection (35.2%), and 19 with mixed infection by these species (2.1%). Results. Leukocyte counts at diagnosis were
within normal range in 79% of patients and 18% had leucopenia; the most frequent alteration was lymphopenia (54%) followed by
monocytosis (11%); the differential granulocyte count in 298 patients revealed eosinophilia (15%) and high basophil counts (8%).
Leukocytosis, eosinopenia, and neutrophilia were associated with clinical complications.The utility of changes in leukocyte counts
as markers of severity should be explored in depth. A better understanding of these hematological parameters will allow their use
in prompt diagnosis of malaria complications and monitoring treatment response.
1. Introduction
Malaria, a disease caused by protozoan parasites of the genus
Plasmodium, is still considered a serious global public health
problem [1]. There were approximately 198 million cases
and 584,000 deaths in 2013, according to the World Health
Organization (WHO) [2]; however it has been noted in recent
years that there is significant underreporting of cases and
deaths worldwide [3]. Fatal cases are mainly attributed to
Plasmodium falciparum; however other plasmodia, like P.
vivax, can cause serious illness and even death [4, 5].
Malaria can affect any organ or system, the hematological
system being themost affected one.Themajority of described
alterations occur on the red cell line and platelets, causing
anemia and thrombocytopenia [6–8]. Alterations in the
white blood cell (WBC) counts are less reported and have
been associated with factors such as severity, Plasmodium
species, concurrent infections, and treatment response [9–
12]. Descriptions of leukocytosis, leukopenia, neutrophilia,
and neutropenia, presence of immature neutrophils, and
changes in lymphocytes, monocytes, and eosinophils in these
patients have been observed [13, 14], but studies have not
shown a specific leukocyte profile alteration in malaria.
It has been found thatWBC counts are generally lower in
malaria patients compared to healthy patients and that there
is a trend towards lower WBC counts in patients infected
with either P. falciparum or P. vivax [15]. Additionally it has
been observed that these changes are dynamic during illness,
with lower lymphocyte and eosinophil counts at baseline
and higher counts as the symptoms disappear [15, 16]. There
have been descriptions of mortality-associated leukocytosis,
presence of coinfections, and gram negative bacteremia in
complicated cases of P. falciparummalaria [17].
Several theories attempt to explain these described hema-
tologic disorders, including (i) bone marrow (BM) suppres-
sion secondary to immune response imbalances, (ii) lower
average cell life, and (iii) leukocyte redistribution to lymphoid
organs and tissues with increased inflammatory response or
sequestration in microvasculature [11, 14, 18–20]. However,
these findings remain poorly understood and their utility in
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clinical practice has not yet been established, unlike for other
infectious diseases prevalent in tropical areas, such asDengue
[21].
The Complete Blood Count (CBC) assesses the cellular
elements of the blood, that is, red cells, white cells, and
platelets, both qualitatively and quantitatively [22] and is
an essential tool in assessing hematological changes. The
leukogram is part of the CBC that analyzes white blood
cells; it comprises the total WBC and subpopulation counts
including neutrophils, eosinophils, basophils, lymphocytes,
and monocytes. Their reference values vary according to
age, race, physiological condition (pregnancy), use of some
drugs, and time of day [23]. The aim of this study is to
characterize changes in the WBC count of patients with
malaria from endemic regions in Colombia and to analyze
variations according to clinical status, species of Plasmodium,
and some sociodemographic characteristics of the patients.
Our purpose is to encourage the use of easily accessible
diagnostic tools, such as the CBC, allowing early identi-
fication of patients at risk for clinical complications and
to implement appropriate therapeutic measures, improving
patient outcome.
2. Methods and Materials
A descriptive retrospective analysis was made with clinical,
laboratory, and demographic data from outpatients with P.
falciparum or P. vivax malaria, from endemic regions in
Colombia. The reference population consisted of patients of
all ages with symptoms suggestive of malaria, with parasito-
logical diagnosis confirmedwith thick blood smear examina-
tion in first or second level of care hospitals and health care
facilities in the municipalities of Turbo and Necocl´ı (Uraba´,
Antioquia), El Bagre (Bajo Cauca, Antioquia), Tumaco,
Guapi, and Timbiquı´ (Pacific Coast), and who were enrolled
in clinical and epidemiological studies conducted by the
Malaria Group between 1997 and 2007 [24–26]. We also
included Medell´ın third-level hospitals’ inpatients’ data from
2005 to 2010, referred from different regions. Convenience
sampling was performed for this analysis; only patients
with a CBC performed at hospital admission were included,
obtaining a sample of 888 patients.
The thick smear examination was done according to
WHO recommendations [27]. After a medical assessment,
a sample of blood was taken in EDTA for cellular and bio-
chemical studies, including aCBCwithin 2 hours, obtained in
3rd- and 4th-generation automated analyzers (Abbott Diag-
nostics Cell-Dyn3200; Beckman Coulter, Coulter HmX; and
Nihon Kohden Celltac MEK, Sysmex KX-21N). Colombian
population reference values for theWBC counts were applied
(Table 1) [28].
TheWBC count, hemoglobin values, and platelets counts
were qualitatively classified as low or high if they were above
or below the normal range. Complications were classified
according to WHO major criteria for severity [29] and to
proposed minor criteria for Colombia [26] as follows:
(1) liver failure: severe liver failure (total bilirubin >3mg/
dL; AST >120 IU/L) or mild liver failure (total bilirubin >
1.5–3mg/dL; AST > 80–120 IU/L); (2) thrombocytopenia:
profound (<25,000 platelets/𝜇L) or severe (25–50,000 plate-
lets/𝜇L); (3) renal impairment: severe (BUN > 60mg/dL or
creatinine > 3mg/dL) or mild (BUN 41–60mg/dL or creat-
inine 1.5–3mg/dL); (4) anemia: severe (hemoglobin < 5 gr/
dL) or moderate (hemoglobin 5–6.9 gr/dL); (5) neurologic
complication: cerebral malaria (seizures/coma) or extreme
weakness; (6) pulmonary injury: acute respiratory distress
syndrome (ARDS)/pulmonary edema or pleural effusion;
(7) acid-base disturbance: severe acidosis (pH < 7.35 and
HCO
3
< 15mEq/L) or acidosis (pH < 7.35 and HCO
3
15–
18mEq/L); and (8) hypoglycemia: severe (<40mg/dL) or
moderate (40–49mg/dL).
Patients were divided into five age groups for analysis.
Parasitemia was classified by ranges of parasites/𝜇L in up
to 1,000; 1,001–5,000; 5,001–10,000; 10,001–50,000; 50,001–
100,000; and greater than 100,000.
2.1. Statistical Analysis. The Kolmogorov-Smirnov test was
used to assess normality for quantitative variables; themedian
values were compared with Mann-Whitney 𝑈 test when
variables were not normal. Associations between qualitative
variables were analyzed with the 𝜒2 test. Spearman’s rank
correlation coefficient was applied to analyze some relation-
ships between numerical data. The adopted level of statistical
significance was 5% (𝑃 value <0.05). The analysis was done
with IBM SPSS statistics program, 22nd version (licensed to
Universidad de Antioquia).
2.2. Ethical Aspects. The patients studied prospectively were
included after giving informed consent, endorsed by the
Ethics Committee of the Medical Research Institute from the
Medical School of the Universidad de Antioquia (Minute 31,
July 2002; Minute 5, June 2005).The review of retrospectively
studied patients’ medical records was approved by the Hospi-
tal Ethics Committees from Hospital Pablo Tobo´n Uribe and
Hospital San Vicente Fundacio´n (Letter 5282, October 2009).
3. Results
Blood counts of 888 patients were analyzed. The quantitative
variables showed normal distribution, except hemoglobin
(KS, 𝑃 = 0.082).The sample consistedmostly of men (62.8%)
over 15 years of age, with a mean age of 26 years (median
22.8). Age ranged from 1 month to 82 years. The geographic
origin of the patients is shown in Figure 1. Some demographic
characteristics are described in Table 2.
The time of disease progression to first medical consul-
tation was known for 618 patients: 30% (𝑛 = 185) consulted
within the first three days of onset of symptoms, 44.9% (𝑛 =
277) between days 4 and 7, and 21.3% (𝑛 = 132) from
day 8 to 15; 3.8% of the study population consulted 2 weeks
after the onset of symptoms. Previous use of antimicrobials
was established (not antimalarial) in 39 (4.4%) patients
(particularly penicillins in 23 and cephalosporins in 7) and
antimalarials in 79 (8.9%) (particularly chloroquine and
primaquine in 68 and quinine in 8). Complicatedmalaria was
diagnosed in 257 patients (29%): 110 (12%) withmajor criteria
and 147 (16.6%) with minor criteria for severity; no deaths
were reported.
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Table 1: Leukogram reference values by age∗.
Age Leukocytes/𝜇L Neutrophils/𝜇L Lymphocytes/𝜇L Monocytes/𝜇L Eosinophils/𝜇L Basophils/𝜇L
1–15 days 9,000–30,000 1,000–12,000 3,000–9,000 30–750 40–500 0–50
16–31 days 5,000–21,000 1,000–12,000 3,000–9,000 30–750 40–500 0–50
1–12 months 6,000–17,500 1,000–12,000 3,000–9,000 30–750 40–500 0–50
1–5 years 5,500–15,500 1,700–7,500 3,000–9,000 30–750 40–500 0–50
6–14 years 4,500–14,500 1,500–6,500 2,000–7,200 30–750 40–500 0–50
15–99 years 4,500–11,000 1,500–8,000 1,500–4,000 30–900 40–500 0–50
∗Leukogram counts based on gender not shown.
Adapted from [28].
Table 2: Demographic characteristics of 888 malaria patients from
Colombia.
Characteristics 𝑛 %
Gender
Male 558 63
Female 330 37
Age
Less than 1 year 8 0.9
1.1 to 5 years 50 5.6
5.1 to 15 years 193 21.7
15.1 to 65 years 624 70.3
Over 65 years 13 1.5
3.1. Parasite Counts Description. P. falciparum infection was
diagnosed in 556 patients (62.6%); P. vivaxwas in 313 (35.2%)
andmixed infection by these species in 19 (2.1%).Themedian
parasite count in 809 patients was 4,980/𝜇L; 71.8% (𝑛 = 581)
had counts lower than 10,000 parasites/𝜇L and 1% (𝑛 = 8) had
parasitemia above 100,000/𝜇L. In parasitemia ranges, 19.9%
had less than 1,000 parasites/𝜇L, 51.8% between 1,000 and
10,000, 24.5% between 10,001 and 50,000, and 2.7% between
50,000 and 100,000.
3.2. Leukogram Findings. Leukocyte subpopulations were
not normally distributed (KS, 𝑃 < 0.001); leukocyte counts
at diagnosis were within the normal range in 79% (𝑛 = 698)
of patients and 18% (𝑛 = 157) had leucopenia; the median
value for these cells was 6,100/𝜇L. Figures 2 and 3 show
subpopulation frequency distribution. Patients with previous
use of antimicrobials had a higher frequency of leukopenia
than those not taking any (35.9% versus 16.8%) (OR = 2.9;
1.4–5.7; 𝑃 = 0.002); the former had lower leukocyte counts
than the latter (Mann-Whitney 𝑈 test; 𝑃 = 0.016).
Mononuclear Cells. Lymphopenia prevailed in 54% (𝑛 = 476);
themedian value for these cellswas 1,575/𝜇L.Monocyte count
was normal in 85% of cases (𝑛 = 749); the median count was
371 cells/𝜇L.
Granulocytes (PMN). Some of the analyzed blood counts did
not have differential granulocyte subpopulations counts and
only had a total granulocyte count. Normal values were found
in 91% of patients (𝑛 = 805). One-third of differential counts
came from severe patients and the rest from nonsevere ones
(66%)
Analyzed neutrophils in 446 patients showed normal
values in 91% of cases (𝑛 = 407); the median value was
3,836 cells/𝜇L. Only 250 patients had eosinophil counts of
which 80% (𝑛 = 201) were normal and 15% (𝑛 = 37) had
eosinophilia; the median value for these cells was 176/𝜇L.
Eosinopenia was present in 5% (𝑛 = 12) of patients. Only 268
patients had basophil counts, of which 92% (𝑛 = 246) were
within normal values. No patient in this group had counts
below normal levels.
3.2.1. Age of Patients. Themedian neutrophil value was lower
in children; there was greater variability in their counts with
the highest individual neutrophil counts.Means andmedians
are presented in Table 3. No significant differences between
groups were observed when values were assigned into the
categories of normal, low, or high (𝑃 > 0.05). Children
were more likely to have monocytosis (RR = 2.2, 1.4–3.5;
𝑃 < 0.001), neutrophilia (RR = 2.3, 1.0–5.2; 𝑃 = 0.046),
and eosinophilia (RR = 2.2, 1.1–4.5; 𝑃 = 0.029) than adults
(Table 4).
3.2.2. Parasitemia and Plasmodium Species. There was a
negative relationship between the number of parasites and
the eosinophil count (Spearman coefficient −0.2; 𝑃 = 0.010);
no linear correlation was found with other cell populations.
There were no differences in leukocyte subpopulations medi-
ans in relation to plasmodial species (𝑃 > 0.05) (Table 3).
3.2.3. Severe Malaria. Neutrophilia and eosinopenia were
the most common alterations in severe malaria cases. The
comparison between severe malaria (overall complications,
diagnosed with major or minor criteria) and nonsevere
malaria shows that leukopenia and leukocytosis, lymphope-
nia, eosinopenia, monocytosis, and neutrophilia were linked
to severity (Table 5). These associations remained when only
major criteria were applied, except for leukocytosis. When
only minor criteria were applied, leukopenia (OR = 1.7; 1.1–
2.6; 𝑃 = 0.022), leukocytosis (OR = 2.5; 1.01–2.6; 𝑃 =
0.039), lymphopenia (OR = 2.2; 1.5–3.2; 𝑃 < 0.001), and
eosinopenia (OR = 10.8; 2.1–55.6; 𝑃 = 0.002) were associated
with severity. Leucocyte counts are compared in relation to
clinical condition in Table 6.
3.2.4. Glycemia and Leukocytes. Glycemia values were
obtained from 357 subjects, averaging 107.6mg/dL (37–264)
with a median of 102mg/d. When glycemia was compared
with leukocyte counts, patients with leucopenia had
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n = 17 (1.9%)
Urabá Antioqueño
n = 402 (45.3%)
Urabá Chocoano
n = 8 (0.9%)
Bajo Cauca Antioqueño
n = 277 (31.2%)
Pacífico Chocoano
n = 27 (3%)
Pacífico
n = 147 (16.6%)
Amazonía
n = 3 (0.3%)
Alto Sinú–Costa Atlántica
Figure 1: Geographical location of patients’ residence byColombianmalarial endemic regions. Obtained andmodified from theCartographic
Design Unit of the World Bank, 2000.
17.7%
3.6%
53.8%
4.9%
78.6%
91.0%
44.2%
84.6%
3.7% 5.4% 2.0%
10.5%
Low
Normal
High
Monocytes
(n = 885)
Lymphocytes
(n = 885)
Granulocytes
(n = 885)
Leukocytes
(n = 888)
Figure 2: Leukocyte counts distributions.
significantly higher blood glucose with a median of 108mg/
dL and those with normal WBC count had a median of
101mg/dL (𝑃 = 0.033, Mann-Whitney); leukopenia patients
had an increased risk of elevated blood sugar levels (>140mg/
dL) (OR = 2.6; 1.4–5; 𝑃 = 0.004) compared with patients
with a normal WBC count.
Lymphopenia patients had a median blood glucose of
109mg/dL versus 95mg/dL in patients with normal lympho-
cyte counts (𝑃 < 0.001, Mann-Whitney); lymphopenia was
3.4% 4.8% 0.0% 0.0%
91.3%
80.4%
91.8% 93.2%
5.4%
14.8% 8.2% 6.8%
Low
Normal
High
Bands
(n = 266)
Basophils
(n = 268)
Eosinophils
(n = 250)
Neutrophils
(n = 298)
Figure 3: Granulocyte subpopulations counts.
associated with an increased risk of high blood glucose levels
(>140mg/dL) (OR = 2.8; 1.3–5.7; 𝑃 = 0.007).
Low granulocyte counts were related to lower blood
glucose values, with amedian of 81mg/dL versus 103mg/dL in
patients with normal granulocyte counts (𝑃 = 0.002, Mann-
Whitney), but the values remained within normal ranges.
There was no higher risk of high blood glucose (𝑃 < 0.05)
in patients with low granulocyte counts.
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Table 4: White blood cells per 𝜇L in children and adults.
Cell group Children Adults
Leukocytes (medians) 6.650 (𝑛 = 252) (IR∗ = 3,675) 6.000 (𝑛 = 636) (IR = 2,800)
Lymphocytes (medians) 2.030 (𝑛 = 251) (IR = 1,835) 1.442 (𝑛 = 634) (IR = 1,109)
Monocytes (medians) 400 (𝑛 = 251) (IR = 3,675) 348 (𝑛 = 435) (IR = 351)
Neutrophils (medians) 3.603 (𝑛 = 130) (IR = 2,154) 3,927 (𝑛 = 316) (IR = 2,371)
Eosinophils (medians) 204 (𝑛 = 79) (IR = 375) 168 (𝑛 = 171) (IR = 261)
Basophils (mean value) 17 (𝑛 = 87) (CI∗∗ = 5–30) 18 (𝑛 = 181) (CI = 4–31)
Bands (mean value) 34 (𝑛 = 87) (CI = (−3)–70) 23 (𝑛 = 179) (CI = 11–36)
∗Interquartile ranges.
∗∗95% confidence interval.
Table 5: Comparison of leukocyte alterations between complicated and noncomplicated patients.
Normal 𝑛 (%) Low 𝑛 (%) High 𝑛 (%)
Leukocytes
Complication (no) 516 (73.9) 96 (61.1) 19 (57.6)
Complication (yes) 182 (26.1) 61 (38.9) 14 (42.4)
OR (CI), 𝑃∗ 1.8 (1.3–2.6), 0.001 2.1 (1.0–4.2), 0.038
Lymphocytes
Complication (no) 309 (79.0) 309 (64.9) 11 (61.1)
Complication (yes) 82 (21.0) 167 (35.1) 7 (38.9)
OR (CI), 𝑃 2.0 (1.5–2.8), 0.000 2.4 (0.9–6.4), 0.071
Monocytes
Complication (no) 543 (72.5) 32 (74.4) 54 (58.1)
Complication (yes) 206 (27.5) 11 (25.6) 39 (41.9)
OR (CI), 𝑃 0.9 (0.5–1.8), 0.783 1.9 (1.2–3.0), 0.003
Neutrophils
Complication (no) 278 (68.3) 11 (73.3) 10 (41.7)
Complication (yes) 129 (31.7) 4 (26.7) 14 (58.3)
OR (CI), 𝑃 0.8 (0.3–2.5), 0.680 3.0 (1.3–6.9), 0.007
Eosinophils
Complication (no) 133 (66.2) 2 (16.7) 29 (78.4)
Complication (yes) 68 (33.8) 10 (83.3) 8 (21.6)
OR (CI), 𝑃 9.8 (2.0–93.2), 0.001∗∗ 0.5 (0.2–1.2), 0.143
∗Odds ratio, confidence interval, and 𝑃 value; ∗∗Fisher’s exact test.
3.2.5. Leukocytes and Other CBC Variables. A direct cor-
relation between the WBC and platelet counts (Spearman
coefficient 0.27, 𝑃 < 0.001) was found. This correlation is
maintained with lymphocytes (0.27; 𝑃 < 0.001), monocytes
(0.14; 𝑃 < 0.001), granulocytes (0.18; 𝑃 < 0.001), neutrophils
(0.12; 𝑃 = 0.016), and eosinophils (0.25; 𝑃 < 0.001). The
median platelet count differed significantly between patients
with leukopenia (100,000/𝜇L; 𝑛 = 154) and those without
leukopenia (131,000/𝜇L; 𝑛 = 704) (𝑃 < 0.001, Mann-
Whitney). Thrombocytopenia defined as a platelet count
<150,000/𝜇Lwas a risk factor for developing leucopenia, both
with (OR = 5.8; 2.7–12.4) and without anemia (OR = 3.7; 0.9–
7.4). Patients with severe thrombocytopenia had significantly
lower leukocyte counts if infected with P. vivax (median
4,850 cells/𝜇L) compared to P. falciparum infections (median
6,100 cells/𝜇L) (𝑃 = 0.011, Mann-Whitney), a difference that
was not observed by species of Plasmodium among patients
without thrombocytopenia.
No correlation between leukocyte and erythrocyte counts
was found (Spearman = 0.032; 𝑃 = 0.364); the median
erythrocyte count did not differ (𝑃 = 0.3133; Mann-
Whitney) between patients with leucopenia (4,365,000/mm3;
𝑛 = 142) and those without leukopenia (4,400,000/mm3;
𝑛 = 620); hemoglobin values did not differ between patients
with leukopenia (11.6mg/dL; 𝑛 = 157) and those without
leukopenia (12.1mg/dL; 𝑛 = 698) (𝑃 = 0.164, Mann-
Whitney). A negative correlation between lymphocyte and
erythrocyte counts (Spearman = −0.18; 𝑃 < 0.001) and
a positive one between lymphocyte and neutrophils counts
(Spearman = 0.18; 𝑃 < 0.001) were found.
A negative relationship between the number of parasites
and the eosinophil count was found (Spearman coefficient
−0.18; 𝑃 < 0.001); no linear correlation was found with other
cell populations.
4. Discussion
Of the studied patients, 70% consulted after three days of
febrile syndrome onset and 66% of the blood counts were
performed between days 4 and 15 of the disease; thus WBC
counts may reflect the response to repeated erythrocytic
schizogony. One of the difficulties in establishing a pattern of
leukocyte alteration during malaria episodes is the presence
of different infection stages when theWBC count is analyzed.
This variation in hematological parameters is expected as
days pass from the onset of infection and may also be the
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Table 6: Leucocyte counts (cells/𝜇L) in relation to clinical condition∗.
Groups Leukocytes Lymphocytes Monocytes Neutrophils Eosinophils
𝑁 Median 𝑃 𝑁 Median 𝑃 𝑁 Median 𝑃 𝑁 Median 𝑃 𝑁 Median 𝑃
Complicated malaria
Yes 257 6,100 0.365 256 1,358 0.000 256 347 0.545 147 4,030 0.114 86 111 0.000
No 631 6,200 629 1,680 629 378 299 3,952 164 242
Hepatic dysfunction
Yes 178 6,200 0.308 178 1,295 0.001 178 373 0.506 105 4,040 0.005 55 124 0.067
No 278 5,800 277 1,526 277 392 173 3,456 69 204
Renal dysfunction
Yes 34 7,400 0.014 34 1,422 0.949 34 457 0.081 26 5,079 0.003 19 158 0.605
No 421 5,900 420 1,449 420 386 253 3,550 105 158
Neurological complication
Yes 17 7,700 0.443 17 1,716 0.319 17 418 0.578 12 3,430 0.658 10 68 0.012
No 871 6,100 868 1,569 868 370 434 3,836 240 186
Pulmonary complication
Yes 17 7,700 0.425 17 1,716 0.218 17 418 0.267 17 4,235 0.560 10 85 0.028
No 871 6,100 868 1,569 868 370 868 3,954 240 186
Severe hypoglycemia (<49 gr/dL)
Yes 4 8,300 0.318 4 807 0.246 4 191 0.209 2 8,009 0.004 1 N.D. 0.147
No 352 5,950 351 1,425 351 366 194 3,672 67 204
Severe anemia
Yes 26 8,000 0.073 26 2,346 0.000 26 453 0.025 14 3,543 0.239 10 163 0.941
No 862 6,100 859 1,540 859 368 432 3,857 240 176
Severe Thrombocytopenia
Yes 93 5,700 0.084 93 1,372 0.069 93 273 0.058 55 3,950 0.918 44 93 0.003
No 765 6,200 762 1,587 762 382 361 3,822 190 205
Acidosis
Yes 12 8,200 0.501 12 1,191 0.091 12 437 0.687 12 5,502 0.170 11 154 0.092
No 20 6,250 20 1,432 20 768 20 3,285 18 73
∗Major or minor criteria for severe malaria.
result of drug administration as observed with the use of
antimicrobials in these patients.
The prevalent Plasmodium species in the cases studied
was P. falciparum, in 63% of patients; this differs from the
epidemiology ofmalaria inColombiawhere the predominant
species is P. vivax, a situation possibly due the fact that more
falciparum cases require hospitalization. Parasitemia ranges
were below 10,000 parasites per microliter in 72% of patients
(approximately less than 0.25% of parasitized erythrocytes).
This variable was not associated with leukocyte alteration,
except for the negative correlation between parasitemia and
eosinophil counts (Spearman, 𝑃 < 0.001).
The leukogram profile was similar in P. vivax and P. falci-
parum malaria. Although a strong inflammatory response in
P. vivax infections has been recognized [30], our study did not
find a differential leukocyte response by Plasmodium species,
except for patientswith severe thrombocytopenia andP. vivax
infection, whose leukocyte counts were significantly lower,
in accordance with previous findings in the acute phase of
infection [31]. Leukopenia is a common finding in falciparum
and vivaxmalaria [15, 16, 32]. Although some studies indicate
that there is a greater trend towards leukopenia in infections
with P. falciparum, this also happens with P. vivax [15, 33, 34].
Therefore the presence of leukopenia or its severity does not
seem to be useful for diagnosis of species.
Although Plasmodium sp. is a hemoparasite, it has been
observed that malaria does not significantly affect WBC
counts, with values that are usually normal for total leukocyte
population for both granulocyte and mononuclear cell sub-
populations. Publications on leukocyte alterations in patients
with malaria mostly reported WBC counts within normal
ranges [9, 32–36]. These findings are consistent with our
results where 85% of patients had normal leukocyte counts.
The leukocyte, lymphocyte, monocyte, and neutrophil counts
differed significantly between children and adults, but the
values were within normal limits; therefore these differences
appear to be due to physiological variability between groups.
Some changes have been reported in the distribution of
WBC lines during the acute phase of malaria infection as well
as the return to normal values during the convalescent phase
[31], and there is a clear normalizing trend of WBC counts
after disease resolution [15], meaning thatWBC counts could
be used as an indicator for the progress of disease, providing
guidance for its management.
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4.1. Leukopenia. Leukopenia is an alteration present in both
falciparum and vivax malaria [15, 16]. Our study found
that leukopenia was more frequent (18%) than leukocytosis
(4%). This is the most reported alteration in malaria with
frequencies up to 22% [13, 34, 36, 37]. Leukopenia (WBC <
6,100 cells/𝜇L) was present in 10.2% [17] of Kenyan children
over 3 months of age, hospitalized with P. falciparummalaria.
Using a cutoff value of <4,000 cells/𝜇L to define leukopenia,
this alteration was observed in 22.1% of infections by P.
vivax and 18.4% of mixed infections [37]. In experimental
infections with P. falciparum, counts under 3,000 cells/𝜇L
were identified in 12% (𝑛 = 83) and counts under 1,000
cells/𝜇L were in 9% (𝑛 = 79) [38]. In the UK leukopenia
was described in 7% of patients with imported P. falciparum
malaria [39].
Leukopenia in malaria can be caused by the interaction
of various events. It has been proposed that the seques-
tration of leukocytes causes the decline in WBC counts
more than a decreased production or accelerated destruction
[11]. Glycosylphosphatidylinositol (GPI), an immunogenic
antigen common to all species of Plasmodium, stimulates the
production of proinflammatory cytokines in monocytes and
macrophages [15, 40]; this would increase phagocytosis gen-
erating cell debris and increasing RBC and WBC phagocy-
tosis, thus maintaining increased proinflammatory cytokine
levels, particularly TNF-𝛼, causing altered hemopoiesis [15,
41, 42].
4.2. Leukocytosis. Leukocytosis frequency in malaria varies
fromone study to another [11–13, 39] and is reported predom-
inantly in falciparummalaria.This alterationwas identified in
4% of our patients, without statistically significant differences
by Plasmodium species (𝑃 > 0.05); the presence of coinfec-
tions that may explain leukocytosis was not studied.
Leukocytosis occurs mainly by increased PMN numbers,
but lymphocytosis, monocytosis, and eosinophilia can also
occur [15, 17, 34]. A study of the cellular composition of BM
[9] concluded that during Plasmodium infection there was
a decrease in some core precursors and in PMN reserves,
with increased circulation of immature PMN (bands) and
abnormalities in their response to stimuli with drugs and
endotoxin; the initial stimulus of infection on theBMreserves
and increased circulating half-life of PMN lead to a transient
leukocytosis. In falciparum malaria, leukocytosis has been
explained by the stimulus of infection on the BM to release
leukocytes during the paroxysms [16]; increased proinflam-
matory cytokines could favor the exit of leukocytes from BM
[14] or by the presence of bacterial or viral coinfections [12],
considering that these possible diagnoses were not excluded
in some of the studies [17].
Comparative studies between severe and nonsevere
malaria point out leukocytosis as a marker of severity and a
predictor of death. AWBC count greater than 16,500 cells/𝜇L
was associatedwith a 7.14 times greater risk of death;mortality
was related to the occurrence of bacteremia, polypnea, and
coma [17]. When comparing severe and nonsevere patients,
leukocytosis was found in 19% of severe and 12.7% of
uncomplicated malaria patients; leukocytosis patients were
younger and had other manifestations of severe malaria such
as hypoglycemia and severe anemia and a 3.5 times greater
risk of dying [12]. In our study 33 patients had leukocytosis
and 42% of them had some complications (OR = 2.01; 1.1–4.2;
𝑃 = 0.040); specifically renal dysfunction was related to this
alteration.
4.3. Lymphocytes. Lymphopenia was the most common
abnormality in our patients, present in 54% of cases, while
only 2% had lymphocytosis; it was associated with throm-
bocytopenia as were lymphopenia and neutropenia (𝑃 <
0.001). In the acute-stage malaria infection lymphopenia
(defined as an absolute lymphocyte count ≤1500 cells/𝜇L)
was common in vivax and falciparum cases [15]. This finding
was similarly reported in 63% of patients with imported
falciparum malaria; and along with thrombocytopenia it
represented the most common alteration [39].
The etiology of lymphopenia is open to discussion; it has
been proposed that during the onset of infection lymphocyte
counts drop due to lymphocyte stimulation through inflam-
mation and their following distribution tomore active tissues
[43] followed by a reorganization of cellular distribution after
disease resolution with a return to normal values [44].
A study in animal models found, however, significant
elevations of serum apoptotic factors such as Fas and FasL in
macaques, which were more susceptible to malaria compli-
cations and developed a more pronounced lymphopenia at
the expense of T cells [45]; these findings were subsequently
confirmed in humans with P. falciparum malaria: samples
from these patients showed higher values of the afore-
mentioned apoptotic factors at diagnosis and a progressive
decrease as the treatment advanced, coinciding with an
increase in lymphocyte counts [46]. Despite these results, a
clear correlation between elevated Fas-FasL and decreased
lymphocytes counts has not been established [47] and both
are believed to be the result of malaria immune hyper-
stimulation causing lymphocyte downregulation to maintain
cellular homeostasis or a strategy of the Plasmodium genus
parasites to decrease immune response [48]. Sequestration of
lymphocytes in organs such as the spleen, presence of atypical
or plasmacytoid lymphocytes, or decreased survival of these
cells have been described [14, 15, 19].
Lymphopenia is a complex pathogenic phenomenon that
may have important clinical effects in patients because of
the transient immunodeficiency state that can occur and
the increased risk of complications [44]; lymphopenia in
our patients was associated, in general, with severity and
specifically with moderate or severe hepatic dysfunction.
4.4. Monocytes and Granulocytes. Reported changes in other
WBC like monocytes and eosinophils are less frequent;
eosinopenia has been reported at malaria diagnosis [14–
16], but, overall, there has been full recovery during the
course of the disease, returning to normal values or even
tending to mild eosinophilia at the end of treatment [16, 48].
In our patients 85% of monocyte and 91% of granulocyte
counts were normal. Monocytosis presented in 11% of cases
and it was associated with severe anemia, in line with the
above findings for lymphocytosis. Although it has been
described that PMNs are largely responsible for the elevation
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of leukocyte counts, a strong association of monocytosis
and lymphocytosis with mortality has been highlighted
[17].
Eosinophilia was the most frequent alteration in granulo-
cytes (15% of 250 patients) while eosinopenia was identified
in 5% of cases, which was associated with severe malaria and
specifically with neurological, pulmonary, and renal compli-
cations and with severe thrombocytopenia. Low eosinophil
levels have been reported in the early stage of acute falciparum
and vivax infections (normal values ≤350 cells/𝜇L), with
increasing levels over the following few weeks [15]. Increased
eosinophil counts have been associated with better recovery
from malaria anemia secondary to allergies caused by drugs
[16] and have also been proposed as an indicator of adequate
response to treatment in malaria patients [14, 15].
Neutrophil counts were normal in 91% of cases, with
neutrophilia prevailing over neutropenia (5% versus 3%);
it was associated with severe malaria and specifically with
severe hypoglycemia andmoderate or severe liver and kidney
dysfunction. Altered basophil counts were not associated
with severity. Although differential granulocyte counts were
not available for all patients, 33% came from severe cases,
which ensures inclusion of complicated and noncomplicated
patients in the analysis.
4.5. Leukocytes, Erythrocytes, and Platelets. Leukocyte chan-
ges were not related to the decrease in erythrocyte counts
and hemoglobin, except for the relation of monocytosis
and lymphocytosis with severe anemia in 26 patients. It
is possible that a larger number of cases of severe anemia
allow identifying other abnormalities in the WBC count.
Platelet count, by contrast, positively correlated with changes
in all the white lines (Spearman correlation, 𝑃 < 0.05)
and total leukocyte lymphocyte, monocyte, and eosinophil
counts were lower in patients with severe thrombocytopenia
though only eosinophils showed statistical significance.These
findings suggest an active role of leukocytes in platelet
sequestration sites, via cellular aggregation, a phenomenon
described for platelets [49] and leukocytes [50].
4.6. Leukocytes and Glycemia. A trend of increasing blood
glucose was observed in patients with leucopenia and the
frequency of hyperglycemiawas higher, with statistical signif-
icance; specifically lymphopenia was associated with higher
blood sugar levels. On the contrary, neutrophilia was associ-
ated with severe hypoglycemia, a complication occurring in
only 4 patients.
5. Conclusions
Malaria hematological changes are diverse and can vary
according to study, Plasmodium species, age, gender, and
other factors. Although some studies have recognized the
relationship between leukocytosis and clinical complications
inmalaria, the general picture involving the role of leukocytes
that may play a key role is not entirely clear. The few
studies that analyze the leukogram profile in malaria do
not delve into the relationships of the leukocyte counts and
the clinical condition of patients. This is one of the largest
series of leukograms published in an attempt to explain
the usefulness of this information as an indicator of sever-
ity.
The leukogram profile was similar in P. vivax and P. falci-
parum malaria. Leukocyte counts were within normal range
in 79% of patients and 18% had leucopenia; the most fre-
quent alteration was lymphopenia (54%) followed by mono-
cytosis (11%). In this study, alterations in leukocyte counts
were related to clinical complications according to major
criteria of severity; specifically lymphopenia, eosinopenia,
monocytosis, and neutrophilia were indicators of serious
injury. Leukopenia, lymphopenia, and eosinopenia were
related to complications in patients with minor criteria, pro-
bably indicating that leukocyte changes begin early and may
suggest the onset of serious injury.
Despite the limitations related to retrospective analysis,
this study contributes to a better compression about the
leukocyte response to plasmodial infection and its relation
with the clinical status. The blood samples were processed
in 3rd- and 4th-generation automated analyzers; this reflects
the technological level and the devices that are available in
endemic regions, used to make treatment decisions. Taking
into account the limitations of the information provided by
these devices, our findings’ information could be used to
recognize clinical deterioration and to provide adequate care
and support.
This study determined changes in the WBC count of
malaria patients and analyzed variations according to clinical
status. Some alterations in the WBC profile were related
to clinical severity and could allow early identification of
patients at risk for medical complications. Their utility as
markers of severity should be explored in depth, in addition
to their application, to identify disease resolution. A better
understanding of these hematological parameters will allow
their use in early diagnosis of malaria complications and
monitoring treatment response.
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